Gapping down
In reaction to disappointing earnings/guidance: LF -20.3%, KUTV -20.1%, XONE -9.2%, FRD -0.9%
Select EU related names showing weakness: AEG -2.5%, STM -2.4%, UL -2.2%, UN -2%, CRH -1.8%, TOT -1.7%, ASML -1.7%, SNY -1.7%, SAN -1.6%, CNHI -1.4%, ALU -1.3%, AZN -1.3%, GSK -1.3%, RDS.A -1.2%, DB -0.9%
Other news: AVEO -15.7% ( receives written feedback from the FDA regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer ), NBG -5.3% (continued uncertainty in Greece/IMF talks), LTBR -4.3% (filed for $75 mln mixed securities shelf offering), FRO -2.8% (filed $100 mln mixed securities shelf offering and for a 55 mln ordinary share offering by selling shareholders ), PHG -2.2% (issued response last night To ResMed (RMD) update on Phase IV Serve-hf study), UAL -1.7% (still checking), AXON -1.4% (pulling back after yesterday's IPO), TRXC -1.3% (prices offering of 16,666,667 shares of its common stock at a public offering price of $3.00 per share), ALR -0.5% (announced pricing of $425 mln of 6.375% senior subordinated notes due 2023)
Analyst comments: GMCR -1.7% (downgraded to at ), VOD -0.8% (downgraded to Underweight at Santander
)
In reaction to disappointing earnings/guidance: LF -20.3%, KUTV -20.1%, XONE -9.2%, FRD -0.9%
Select EU related names showing weakness: AEG -2.5%, STM -2.4%, UL -2.2%, UN -2%, CRH -1.8%, TOT -1.7%, ASML -1.7%, SNY -1.7%, SAN -1.6%, CNHI -1.4%, ALU -1.3%, AZN -1.3%, GSK -1.3%, RDS.A -1.2%, DB -0.9%
Other news: AVEO -15.7% ( receives written feedback from the FDA regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer ), NBG -5.3% (continued uncertainty in Greece/IMF talks), LTBR -4.3% (filed for $75 mln mixed securities shelf offering), FRO -2.8% (filed $100 mln mixed securities shelf offering and for a 55 mln ordinary share offering by selling shareholders ), PHG -2.2% (issued response last night To ResMed (RMD) update on Phase IV Serve-hf study), UAL -1.7% (still checking), AXON -1.4% (pulling back after yesterday's IPO), TRXC -1.3% (prices offering of 16,666,667 shares of its common stock at a public offering price of $3.00 per share), ALR -0.5% (announced pricing of $425 mln of 6.375% senior subordinated notes due 2023)
Analyst comments: GMCR -1.7% (downgraded to at ), VOD -0.8% (downgraded to Underweight at Santander
)